Intra-Cellular Therapies, Inc.

ITCI

N/A

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

3 upcoming, 0 past

⭐Phase 3Next

Lumateperone Phase 3 Results Expected

March 2026~Lumateperone350

Primary completion for Lumateperone trial (NCT06462586) in Bipolar Disorder, Manic

Source

⭐Phase 3

Lumateperone Phase 3 Results Expected

May 2026~Lumateperone350

Primary completion for Lumateperone trial (NCT06462612) in Bipolar Disorder, Manic

Source

⭐Phase 3

Lumateperone Phase 3 Results Expected

September 2026~Lumateperone470

Primary completion for Lumateperone trial (NCT05850689) in Major Depressive Disorder

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Risperidone

Phase 3

Schizophrenia

ITI-007

Phase 3

Schizophrenia

Lumateperone

Phase 3

Major Depressive Disorder

Lumateperone low dose

Phase 3

Irritability Associated With Autism Spectrum Disorder

Lumateperone 42 mg

Phase 3

Schizophrenia

Lumateperone (ITI-007)

Phase 3

Bipolar Depression

Lumateperone high dose

Phase 3

Irritability Associated With Autism Spectrum Disorder

ITI-007 (Lumateperone)

Phase 3

Bipolar Depression

ITI-1284 20 mg

Phase 2

Generalized Anxiety Disorder

ITI-1284

Phase 2

Agitation Associated With Alzheimer's Dementia

Lenrispodun

Phase 2

Parkinson Disease

ITI-1284 10 mg

Phase 2

Generalized Anxiety Disorder

ITI-214

Phase 2

Heart Failure, Systolic

Drug Name	Phase	Indication	Designations
Risperidone	Phase 3	Schizophrenia	-
ITI-007	Phase 3	Schizophrenia	-
Lumateperone	Phase 3	Major Depressive Disorder	-
Lumateperone low dose	Phase 3	Irritability Associated With Autism Spectrum Disorder	-
Lumateperone 42 mg	Phase 3	Schizophrenia	-
Lumateperone (ITI-007)	Phase 3	Bipolar Depression	-
Lumateperone high dose	Phase 3	Irritability Associated With Autism Spectrum Disorder	-
ITI-007 (Lumateperone)	Phase 3	Bipolar Depression	-
ITI-1284 20 mg	Phase 2	Generalized Anxiety Disorder	-
ITI-1284	Phase 2	Agitation Associated With Alzheimer's Dementia	-
Lenrispodun	Phase 2	Parkinson Disease	-
ITI-1284 10 mg	Phase 2	Generalized Anxiety Disorder	-
ITI-214	Phase 2	Heart Failure, Systolic	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

ITCI News